OTCMKTS:NSPX

Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
29.64 million shs
Average Volume
13.19 million shs
Market Capitalization
$1.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Inspyr Therapeutics

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

NSPX Stock News Headlines

EWTX Edgewise Therapeutics, Inc.
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
See More Headlines
Receive NSPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2017
Today
4/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:NSPX
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-6,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.07) per share

Miscellaneous

Free Float
N/A
Market Cap
$1.47 million
Optionable
Not Optionable
Beta
-17.33
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Silvestre Raul
    President, Chief Executive Officer & Director
  • Michael Elliott
    Vice President-Clinical Operations

NSPX Stock Analysis - Frequently Asked Questions

How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) posted its earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share for the quarter.

When did Inspyr Therapeutics' stock split?

Inspyr Therapeutics shares reverse split before market open on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Inspyr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Danaher (DHR), Co-Diagnostics (CODX), Cleveland BioLabs (CBLI), Cloudcall Group (CALL), Blink Charging (BLNK) and BIO-key International (BKYI).

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NSPX) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners